We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Evotec and Merck KGaA to Collaborate on Neurological Disease Target
News

Evotec and Merck KGaA to Collaborate on Neurological Disease Target

Evotec and Merck KGaA to Collaborate on Neurological Disease Target
News

Evotec and Merck KGaA to Collaborate on Neurological Disease Target

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Evotec and Merck KGaA to Collaborate on Neurological Disease Target"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Evotec AG has announced that it has signed within the “NEU²-Consortium” framework and partially funded by the Federal Ministry of Education and Research (Bundesministerium fuer Bildung und Forschung - BMBF), an agreement with Merck KGaA, Darmstadt, Germany, to develop pre-clinical candidates for an undisclosed neurological disease.

Evotec will provide drug discovery expertise covering in vitro biology, medicinal chemistry and in vitro and in vivo pharmacology.

As part of the collaboration, Evotec will apply their integrated drug discovery expertise and technologies to identify interesting small molecules for the selected target. The molecules will be further optimized and progressed through lead optimization to a pre-clinical candidate.

Dr Mario Polywka, COO of Evotec commented: “We are proud to be part of the NEU² consortium and we are extremely pleased that Merck KGaA selected Evotec to collaborate on this interesting Drug Discovery Program which is a further recognition of our CNS disease expertise.”
Advertisement